Scholarlink

Purpose <p>Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options, especially after the failure of first-line (1L) platinum-based chemotherapy. This study evaluated the treatment patterns and survival outcomes of Taiwanese patients with SCLC following 1L treatment failure, focusing on the effects of treatment-free interval (TFI).</p> Methods <p>This retrospective study enrolled 287 patients with SCLC from 2012 to 2021. Data on clinical characteristics, systemic treatments after 1L failure, and survival status were collected. Progression-free survival (PFS) and overall survival (OS) were examined in analyses stratified by TFI. TFI &lt; 90 days and ≥ 90 days denoted resistant relapse and sensitive relapse, respectively.</p> Results <p>Second-line (2L) and third-line (3L) chemotherapy was administered to 76% and 54.1% of patients, respectively. Topotecan was administered to 25.4% of patients, primarily those with TFI 90–179 days. Platinum rechallenge was administered to 8.4% of patients, primarily those with TFI ≥ 180 days. The median PFS of patients with 2L treatment was 2.3 months (95% CI 2.2–2.6), and the median OS was 5.1 months (95% CI 4.3–6.2). Patients with TFI ≥ 90 days had significantly longer PFS (2.6 vs 2.2 months, P = 0.011) and OS (9.6 vs 4.0 months, P &lt; 0.0001) than did those with TFI &lt; 90 days. Platinum rechallenge showed similar efficacy to topotecan in patients with sensitive relapse (3.0 vs 2.7 months, P = 0.61).</p> Conclusions <p>Survival outcomes in patients with relapsed SCLC remain poor, particularly in those with platinum-resistant relapse. Our findings highlight the importance of optimizing 1L treatment for delaying disease progression. More effective 2L therapies should be developed to improve survival outcomes in patients with relapsed SCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment patterns and survival outcomes in patients with small-cell lung cancer following failure of first-line platinum-based chemotherapy

  • 期刊论文

  • 发表日期：

    2025年4月10日

查看全文
  • Chi-Lu Chiang,
  • Ying-Ting Liao,
  • Ruei-Lin Sun,
  • Hsu-Ching Huang,
  • Chia-I Shen,
  • Yen-Han Tseng,
  • Yung-Hung Luo,
  • Yuh-Min Chen

摘要

Purpose

Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options, especially after the failure of first-line (1L) platinum-based chemotherapy. This study evaluated the treatment patterns and survival outcomes of Taiwanese patients with SCLC following 1L treatment failure, focusing on the effects of treatment-free interval (TFI).

Methods

This retrospective study enrolled 287 patients with SCLC from 2012 to 2021. Data on clinical characteristics, systemic treatments after 1L failure, and survival status were collected. Progression-free survival (PFS) and overall survival (OS) were examined in analyses stratified by TFI. TFI < 90 days and ≥ 90 days denoted resistant relapse and sensitive relapse, respectively.

Results

Second-line (2L) and third-line (3L) chemotherapy was administered to 76% and 54.1% of patients, respectively. Topotecan was administered to 25.4% of patients, primarily those with TFI 90–179 days. Platinum rechallenge was administered to 8.4% of patients, primarily those with TFI ≥ 180 days. The median PFS of patients with 2L treatment was 2.3 months (95% CI 2.2–2.6), and the median OS was 5.1 months (95% CI 4.3–6.2). Patients with TFI ≥ 90 days had significantly longer PFS (2.6 vs 2.2 months, P = 0.011) and OS (9.6 vs 4.0 months, P < 0.0001) than did those with TFI < 90 days. Platinum rechallenge showed similar efficacy to topotecan in patients with sensitive relapse (3.0 vs 2.7 months, P = 0.61).

Conclusions

Survival outcomes in patients with relapsed SCLC remain poor, particularly in those with platinum-resistant relapse. Our findings highlight the importance of optimizing 1L treatment for delaying disease progression. More effective 2L therapies should be developed to improve survival outcomes in patients with relapsed SCLC.